Summary & Overview
HCPCS J1428: Eteplirsen Injection, 10 mg
HCPCS Level II code J1428 denotes a 10 mg injection of eteplirsen, a disease-modifying therapy administered parenterally. Nationally, biologic and specialty drug billing codes like J1428 matter because they drive coverage determinations, prior authorization requirements, and high-cost drug utilization trends across commercial and public payers. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will learn what J1428 represents clinically and operationally, plus the payer landscape and typical billing considerations associated with high-cost injectable therapies. The publication summarizes benchmarks and payer coverage patterns, highlights relevant policy and coding issues affecting administration and reimbursement of specialty injectable medications, and provides clinical context for use in outpatient infusion or clinic settings. Data not available in the input is noted where specific payer policies, utilization metrics, or diagnosis linkages are required.
Billing Code Overview
HCPCS Level II code J1428 represents injection, eteplirsen, 10 mg. This code is used to bill for administration of the medication eteplirsen when supplied as a 10 mg dose.
-
Service type: Medication injection
-
Typical site of service: Infusion or outpatient clinic setting where parenteral medications are administered
Clinical & Coding Specifications
Clinical Context
A typical patient is a male child or young adult with Duchenne muscular dystrophy (DMD) caused by a confirmed mutation amenable to exon 51 skipping. The patient presents to a specialty neuromuscular clinic or infusion center for scheduled intravenous administration of eteplirsen. The clinical workflow includes medication verification and insurance authorization, baseline vital signs and assessment of weight and infusion access, preparation of J1428 (eteplirsen, 10 mg) by pharmacy under sterile technique, administration via IV infusion with monitoring for infusion reactions, documentation of lot number and dose administered, and post-infusion observation before discharge. Visits typically occur in an outpatient hospital infusion center, ambulatory infusion clinic, or specialty physician office with infusion capability. Coordination involves the neuromuscular specialist, infusion nurse, clinical pharmacist, and billing staff to apply appropriate modifiers and diagnosis linkage for reimbursement with payors such as Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Modifier not otherwise specified (carrier-specific) | Rarely used; follow payor guidance when no other modifier applies |